PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
All Product Categories
-
PROTACs Related Products (1334)
Related Products (1334)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
PROTAC BRD4 Degrader-33
0 ImagesCat. No.: HY-174811PROTAC BRD4 Degrader-33 is an enzyme activated clickable BRD4 PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model.
-
PROTAC FLT-3 degrader 4
0 ImagesCat. No.: HY-158325CAS No.: 2956722-48-6PROTAC FLT-3 degrader 4 is an orally active CRBN-based FLT3-PROTAC degrader that potently induces FLT3-ITD degradation through the ubiquitin-proteasome system. PROTAC FLT-3 degrader 4 shows highly selective to FLT3-ITD mutant acute myeloid leukemia (AML) cells. (Blue: CRBN ligand, Black: linker; Pink: FLT3 inhibitor).
-
PROTAC METTL3-14 degrader 1
0 ImagesCat. No.: HY-162282CAS No.: 3039554-79-2PROTAC METTL3-14 degrader 1 is a METTL3-METTL14 heterodimer complex PROTAC degrader. PROTAC METTL3-14 degrader 1 binds to the E3 ubiquitin ligase CRBN, forms a ternary complex with METTL3-METTL14, and promotes the ubiquitination and degradation of METTL3. PROTAC METTL3-14 degrader 1 is applicable to the research of acute myeloid leukemia and prostate cancer.
-
PROTAC BRD4 Degrader-21
0 ImagesCat. No.: HY-156566CAS No.: 2503036-46-0PROTAC BRD4 Degrader-21 is a BRD4-targeting PROTAC degrader with an IC50 value of 59 nM. PROTAC BRD4 Degrader-21 induces ubiquitination of BRD4, leading to its degradation via the proteasome. PROTAC BRD4 Degrader-21 binds to recombinant HSP90α protein with moderate affinity, having an IC50 of 100-1000 nM. PROTAC BRD4 Degrader-21 induces cancer cell death. PROTAC BRD4 Degrader-21 inhibits tumor growth in xenograft mouse models. PROTAC BRD4 Degrader-21 can be used for the research of acute myeloid leukemia, diffuse large B-cell lymphoma.
-
SH-26
0 ImagesCat. No.: HY-183995SH-26 is a PHD1 PROTAC degrader with DC50s of 1.06 μM, 4.16 μM and 4.91 μM in MDA-MB-231, HepG2 and HEK-293T cells, respectively. SH-26 recruits CRBN to induce PHD1 degradation via the ubiquitin-proteasome system. SH-26 attenuates APAP (HY-66005)-triggered ROS accumulation, mitochondrial dysfunction, and NLRP3 inflammasome activation. SH-26 can be used for the research of acute liver injury.
-
MRC71
0 ImagesCat. No.: HY-180547CAS No.: 3070832-68-4MRC71 is a TRIMTAC degrader that recruits endogenous TRIM21 E3 ligase at one end and covalently binds to HaloTag-fusion target proteins at the other end. MRC71 selectively degrades oligomeric CAV1- and Cavin1-mEGFP-Halo, but not monomeric mEGFP-Halo, and exhibits a typical concentration-dependent degradation profile with a hook effect. MRC71 can be used to verify TRIMTAC ternary complex formation and state-selective degradation in cells.
-
OICR41114
0 ImagesCat. No.: HY-169389OICR41114 is a WDR5 PROTAC degrader with an EC50 of 40 nM. OICR41114 binds both DCAF1 and WDR5, and its binding affinity for DCAF1 is significantly enhanced in the presence of WDR5 (KD increases from 59 nM to 5 nM). OICR41114 exerts antiproliferative effects on MV4-11 cells. OICR41114 can be used for the research of acute myeloid leukemia.
-
PROTAC MAGL degrader-1
0 ImagesCat. No.: HY-173369PROTAC MAGL degrader-1 is an orally active PROTAC agent that simultaneously targets monoacylglycerol lipase (MAGL) and E3 ubiquitin ligase MDM2. PROTAC MAGL degrader-1 degrades MAGL and inhibits the binding of MDM2 to p53. PROTAC MAGL degrader-1 can partially penetrate the blood-brain barrier (BBB). PROTAC MAGL degrader-1 induces glioblastoma stem cells (GSCs) apoptosis.
-
Lw13
0 ImagesCat. No.: HY-162589Lw13 is a Hsp90 PROTAC degrader. Lw13 induces Hsp90 degradation via the ubiquitin-proteasome system, destabilizes client proteins HER2 and AKT, and blocks the activation of the HER2/AKT/mTOR signaling pathway. Lw13 inhibits the metastasis of cervical cancer cells, induces cell cycle arrest and apoptosis (apoptosis). Lw13 exerts synergistic anti-tumor activity with Cisplatin (HY-17394). Lw13 is applicable to cervical cancer-related research.
-
PROTAC PLK1 Degrader-3
0 ImagesCat. No.: HY-181000CAS No.: 3074520-74-1PROTAC PLK1 Degrader-3 (Compound DD-1) is a PLK1 PROTAC degrader based on the N-deglycosylation pathway, with a Kd value of 2.2 μM. The cell penetration ability of PROTAC PLK1 Degrader-3 is limited and a higher concentration is required to achieve significant degradation effects. PROTAC PLK1 Degrader-3 can be used for research on non-small cell lung cancer.
-
PROTAC STING Degrader-2
0 ImagesCat. No.: HY-158036CAS No.: 3023095-61-3PROTAC STING Degrader-2 is a STING PROTAC degrader with a DC50 of 0.53 μM. PROTAC STING Degrader-2 reduces the phosphorylation levels of TBK1 and IRF3. PROTAC STING Degrader-2 decreases the mRNA expression levels of IFN-β, CXCL10 and TNF-α, and blocks luciferase secretion. PROTAC STING Degrader-2 can be used in the research of autoimmune diseases.
-
PROTAC YTHDC1 Degrader-1
0 ImagesCat. No.: HY-184495PROTAC YTHDC1 Degrader-1 is a selective, CRBN-recruiting YTHDC1 PROTAC degrader with a DC50 of 11.42 nM. PROTAC YTHDC1 Degrader-1 induces ubiquitination and degradation of YTHDC1. PROTAC YTHDC1 Degrader-1 induces G1 phase arrest and inhibits cell cycle progression. PROTAC YTHDC1 Degrader-1 also induces Apoptosis. PROTAC YTHDC1 Degrader-1 exhibits anticancer activity against leukemia. PROTAC YTHDC1 Degrader-1 can be used for the research of acute myeloid leukemia.
-
HC278
0 ImagesCat. No.: HY-185230CAS No.: 3096503-40-8HC278 is a selective TEAD1/TEAD3 PROTAC degrader. HC278 induces proteasome-dependent degradation by forming a stable ternary complex with CRBN/DDB1. HC278 is applicable to the research of mesothelioma.
-
PROTAC CDK9 degrader-11
0 ImagesCat. No.: HY-170978CAS No.: 3039540-19-4PROTAC CDK9 degrader-11 is an orally active, selective CDK9 PROTAC degrader with a DC50 of 1.09 nM. PROTAC CDK9 degrader-11 recruits CRBN to form a ternary complex and degrades CDK9 via the ubiquitin-proteasome pathway, thereby inhibiting RNA polymerase II phosphorylation and downregulating the expression of anti-apoptotic and pro-oncogenic genes, ultimately inducing apoptosis. PROTAC CDK9 degrader-11 is suitable for research on small-cell lung cancer (SCLC).
-
PROTAC NTRK1 degrader-1
0 ImagesCat. No.: HY-181052CAS No.: 2922274-35-7PROTAC NTRK1 degrader-1 is a wild-type and mutant NTRK1 PROTAC degrader with IC50 values of 4 nM (wild-type), 2 nM (G595R), 5 nM (G667C), and <0.5 nM (F598L). PROTAC NTRK1 degrader-1 catalyzes ubiquitination and subsequent proteasome-mediated degradation of wild-type and mutant (G595R, G667C, F598L) NTRK1. PROTAC NTRK1 degrader-1 can be used for the research of solid tumors.
-
BRD-SF2
0 ImagesCat. No.: HY-161368CAS No.: 3050690-26-8BRD-SF2 is a BRD4-targeted PROTAC degrader (DC50: 17.2 μM) (Blue: VHL ligand, black: linker, pink: BRD4 ligand).
-
DA-PROTAC
0 ImagesCat. No.: HY-147373CAS No.: 2488660-12-2DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research.
